We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

DiscoveRx Provides PathHunter™ Technology to NIH

DiscoveRx Provides PathHunter™ Technology to NIH

DiscoveRx Provides PathHunter™ Technology to NIH

DiscoveRx Provides PathHunter™ Technology to NIH

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DiscoveRx Provides PathHunter™ Technology to NIH "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DiscoveRx has announced that it has signed an agreement with the National Institutes of Health which will provide initial access to their PathHunter technology for small molecule screening against selected targets of interest to the Molecular Libraries Roadmap Initiative.

PathHunter is a cell-based assay technology ideally suited to high throughput screening that monitors cell signaling pathways.

The movement of proteins is monitored in a homogenous assay format within the cell using positional complementation.

This approach has been applied to a range of target molecules of interest to drug discovery, including kinases, transcription factors, phosphatases and nuclear hormone receptors, and offers a convenient, non-imaging assay format that is amenable to high throughput automation systems.

“We are very pleased to be working with the NIH Chemical Genomics Center to help accelerate their screening efforts,” stated Dr. Richard Eglen, CSO of DiscoveRx.

“We believe that our technology addresses many of the key benefits of more complex cell-based assays that employ imaging, but in a format specifically optimized for higher throughput screening campaigns.”

“Our EFC technology is a proven in vitro biochemical screening method, and the PathHunter products now apply this technology in a novel, whole-cell assay.”